iodine has been researched along with Carcinoma, Medullary in 7 studies
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.
diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..
Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase II study to assess the efficacy of continuous dosing of sunitinib in patients with flurodeoxyglucose positron emission tomography (FDG-PET)-avid, iodine-refractory well-differentiated thyroid carcinoma (WDTC) and medullary thyroid cancer (MTC) and to assess for early response per FDG-PET." | 9.14 | Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. ( Bauman, JE; Capell, PT; Carr, LL; Eaton, KD; Goulart, BH; Kell, EM; Mankoff, DA; Martins, RG, 2010) |
| "We conducted a phase II study to assess the efficacy of continuous dosing of sunitinib in patients with flurodeoxyglucose positron emission tomography (FDG-PET)-avid, iodine-refractory well-differentiated thyroid carcinoma (WDTC) and medullary thyroid cancer (MTC) and to assess for early response per FDG-PET." | 5.14 | Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. ( Bauman, JE; Capell, PT; Carr, LL; Eaton, KD; Goulart, BH; Kell, EM; Mankoff, DA; Martins, RG, 2010) |
| "The prevalence and pathology pattern of iodine deficiency (ID) related disorders are influenced by the dietary iodine intake: low iodine leads to thyroid nodular enlargement, to an increase in the incidence of thyroid cancer, an increase in anaplastic carcinomas and to an alteration in the papillary to follicular neoplasia ratio." | 3.81 | Iodine deficiency and thyroid nodular pathology--epidemiological and cancer characteristics in different populations: Portugal and South Africa. ( Castelo Branco, M; Freitas, M; Kalk, WJ; Marques Carreira, I; Santos, JE, 2015) |
| "These data suggest that the potential malignancy of thyroid nodules is not only correlated to the diameter but to other parameters such as the biological difference of thyroid cancer that could be hypothesized in an iodine deficiency area." | 3.71 | [Prevalence and aggressiveness of thyroid carcinoma with diameter less than one centimetre in iodine deficiency areas]. ( Agosti, B; Cappelli, C; Cerudelli, B; Cumetti, D; Morassi, ML; Pelizzari, G; Tironi, A, 2002) |
| "We studied all thyroid cancers notified to the Danish Cancer Registry in the period 1973-1997, focusing on the four most frequent subtypes: papillary, follicular, anaplastic and medullary thyroid cancer." | 1.33 | Iodine intake and incidence of thyroid cancer in Denmark. ( Johansen, C; Knudsen, N; Perrild, H; Sehestedt, T, 2006) |
| "Papillary carcinoma was the predominant histologic type (26-70." | 1.32 | A prospective study of thyroid nodular disease in children and adolescents in western Poland from 1996 to 2000 and the incidence of thyroid carcinoma relative to iodine deficiency and the Chernobyl disaster. ( Breborowicz, D; Breborowicz, J; Harasymczuk, J; Korman, E; Niedziela, M; Rolski, M; Trejster, E; Warzywoda, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, JE | 1 |
| Kalk, WJ | 1 |
| Freitas, M | 1 |
| Marques Carreira, I | 1 |
| Castelo Branco, M | 1 |
| Carr, LL | 1 |
| Mankoff, DA | 1 |
| Goulart, BH | 1 |
| Eaton, KD | 1 |
| Capell, PT | 1 |
| Kell, EM | 1 |
| Bauman, JE | 1 |
| Martins, RG | 1 |
| Niedziela, M | 1 |
| Korman, E | 1 |
| Breborowicz, D | 1 |
| Trejster, E | 1 |
| Harasymczuk, J | 1 |
| Warzywoda, M | 1 |
| Rolski, M | 1 |
| Breborowicz, J | 1 |
| Faggiano, A | 1 |
| Coulot, J | 1 |
| Bellon, N | 1 |
| Talbot, M | 1 |
| Caillou, B | 1 |
| Ricard, M | 1 |
| Bidart, JM | 1 |
| Schlumberger, M | 1 |
| Sehestedt, T | 1 |
| Knudsen, N | 1 |
| Perrild, H | 1 |
| Johansen, C | 1 |
| Rieu, M | 1 |
| Lame, MC | 1 |
| Richard, A | 1 |
| Lissak, B | 1 |
| Sambort, B | 1 |
| Vuong-Ngoc, P | 1 |
| Berrod, JL | 1 |
| Fombeur, JP | 1 |
| Cappelli, C | 1 |
| Agosti, B | 1 |
| Tironi, A | 1 |
| Morassi, ML | 1 |
| Pelizzari, G | 1 |
| Cumetti, D | 1 |
| Cerudelli, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma[NCT01813136] | Phase 2 | 168 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for iodine and Carcinoma, Medullary
| Article | Year |
|---|---|
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Cell Differentiation; Drug Admi | 2010 |
6 other studies available for iodine and Carcinoma, Medullary
| Article | Year |
|---|---|
Iodine deficiency and thyroid nodular pathology--epidemiological and cancer characteristics in different populations: Portugal and South Africa.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Medullary; Carcinoma, Neu | 2015 |
A prospective study of thyroid nodular disease in children and adolescents in western Poland from 1996 to 2000 and the incidence of thyroid carcinoma relative to iodine deficiency and the Chernobyl disaster.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Carcinoma, Medullary; Carcinoma, Papillary; Child; Fe | 2004 |
Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue.
Topics: Adolescent; Adult; Aging; Biological Transport; Carcinoma, Medullary; Carrier Proteins; Cell Divisio | 2004 |
Iodine intake and incidence of thyroid cancer in Denmark.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Adult; Aged; Carcinoma; Carcinoma, Medullary; | 2006 |
Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Calcitonin; Carcinoma, Medullary; Car | 1995 |
[Prevalence and aggressiveness of thyroid carcinoma with diameter less than one centimetre in iodine deficiency areas].
Topics: Adenocarcinoma, Follicular; Biopsy, Needle; Calcinosis; Carcinoma, Medullary; Carcinoma, Papillary; | 2002 |